GoAI
Get started
Tactile Systems Technology, Inc. logo

Tactile Systems Technology, Inc.

TCMD

NASDAQHealthcareMedical - Devices

Open in GoAI

Latest quote

$23.82

+$0.39 · +1.66%

Aug 21, 3:59 PM ET

TCMD company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

90

Deep Value

Momentum

63

Gaining

Sentiment

77

Bullish

Risk resilience

56

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Tactile Systems Technology, Inc. is a medical technology firm that develops and supplies specialized devices to treat chronic health conditions across the United States. Its product portfolio features the Flexitouch Plus system, a pneumatic compression device designed for managing lymphedema. The company also offers the Entre system, a portable pneumatic compression solution for at-home treatment of various venous disorders, including lymphedema, chronic venous insufficiency, and venous leg ulcers. Additionally, Tactile Systems provides the AffloVest, a portable high-frequency chest wall oscillation device used to address retained pulmonary secretions associated with conditions such as bronchiectasis, cystic fibrosis, and certain neuromuscular disorders. Established in 1995, the company maintains its headquarters in Minneapolis, Minnesota.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Sheri Louise Dodd
Listed since
Jul 28, 2016
Employees
1,086

Market position

Volume
356.5K
1.15× average
Average volume
309.39K
Average daily volume
Market cap
537.29M USD
Beta
0.82
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
21.85×
P/B (TTM)
2.41×
P/S (TTM)
1.53×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
74.23%
Operating margin
10.00%
Net margin
7.10%

Financial health

Debt / equity
0.06×
Altman Z-score
8.29
Piotroski F-score
8 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends83%50%17%-15%Gross margin, FY2021: 71.24%Gross margin, FY2022: 71.31%Gross margin, FY2023: 71.11%Gross margin, FY2024: 73.96%Gross margin, FY2025: 75.17%Operating margin, FY2021: -0.85%Operating margin, FY2022: -5.17%Operating margin, FY2023: 6.57%Operating margin, FY2024: 7.57%Operating margin, FY2025: 8.89%Net margin, FY2021: -5.68%Net margin, FY2022: -7.24%Net margin, FY2023: 10.39%Net margin, FY2024: 5.79%Net margin, FY2025: 5.79%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 71.24%. Gross margin FY2022 71.31%. Gross margin FY2023 71.11%. Gross margin FY2024 73.96%. Gross margin FY2025 75.17%. Operating margin FY2021 -0.85%. Operating margin FY2022 -5.17%. Operating margin FY2023 6.57%. Operating margin FY2024 7.57%. Operating margin FY2025 8.89%. Net margin FY2021 -5.68%. Net margin FY2022 -7.24%. Net margin FY2023 10.39%. Net margin FY2024 5.79%. Net margin FY2025 5.79%.

Income trends

Revenue

329.52M USD+12.47%

Operating income

29.28M USD+32.00%

Net income

19.09M USD+12.54%
Income trends across reported periods364.26M USD225.31M USD86.35M USD−52.6M USDRevenue, FY2021: 208.06M USDRevenue, FY2022: 246.79M USDRevenue, FY2023: 274.42M USDRevenue, FY2024: 292.98M USDRevenue, FY2025: 329.52M USDOperating income, FY2021: −1.76M USDOperating income, FY2022: −12.76M USDOperating income, FY2023: 18.04M USDOperating income, FY2024: 22.18M USDOperating income, FY2025: 29.28M USDNet income, FY2021: −11.81M USDNet income, FY2022: −17.87M USDNet income, FY2023: 28.52M USDNet income, FY2024: 16.96M USDNet income, FY2025: 19.09M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 208.06M USD. Revenue FY2022 246.79M USD. Revenue FY2023 274.42M USD. Revenue FY2024 292.98M USD. Revenue FY2025 329.52M USD. Operating income FY2021 −1.76M USD. Operating income FY2022 −12.76M USD. Operating income FY2023 18.04M USD. Operating income FY2024 22.18M USD. Operating income FY2025 29.28M USD. Net income FY2021 −11.81M USD. Net income FY2022 −17.87M USD. Net income FY2023 28.52M USD. Net income FY2024 16.96M USD. Net income FY2025 19.09M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue329.52M USD292.98M USD274.42M USD246.79M USD208.06M USD
Cost of goods sold81.82M USD76.3M USD79.29M USD70.81M USD59.84M USD
Gross profit247.7M USD216.69M USD195.13M USD175.98M USD148.21M USD
Research and development8.48M USD8.83M USD7.82M USD7.09M USD5.66M USD
Selling, general, and administrative209.94M USD183.14M USD169.19M USD167.21M USD143.58M USD
Operating expenses218.42M USD194.51M USD177.09M USD188.73M USD149.98M USD
Interest income3.1M USD3.38M USD1.87M USD60K USD—
Interest expense1.04M USD2.09M USD4.15M USD2.79M USD—
Depreciation and amortization6.64M USD6.8M USD6.5M USD14.43M USD3.68M USD
Operating income29.28M USD22.18M USD18.04M USD−12.76M USD−1.76M USD
Net income19.09M USD16.96M USD28.52M USD−17.87M USD−11.81M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
82%
9 beats, 2 misses, 0 met estimates
Average EPS surprise
+42.86%
11 comparable reports
Latest EPS result
0.34
Estimate 0.14 · Beat by 151.85%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.510.280.05-0.18Q1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 18, 2025: actual 0.4, estimate 0.31, surprise +29.03%, Beat. Q2 2025, reported May 5, 2025: actual -0.13, estimate -0.07, surprise -85.71%, Miss. Q3 2025, reported Aug 4, 2025: actual 0.14, estimate 0.09, surprise +55.56%, Beat. Q4 2025, reported Nov 3, 2025: actual 0.36, estimate 0.16, surprise +125.00%, Beat. Q1 2026, reported Feb 17, 2026: actual 0.46, estimate 0.44, surprise +4.55%, Beat. Q2 2026, reported May 4, 2026: actual -0.08, estimate -0.07, surprise -14.29%, Miss. Q3 2026, reported Aug 10, 2026: actual 0.34, estimate 0.135, surprise +151.85%, Beat. Q4 2026, reported Nov 2, 2026: actual —, estimate 0.31, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates107.74M90.87M74M57.12MQ1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 18, 2025: actual 85.59M USD, estimate 66.82M USD, surprise +28.09%, Beat. Q2 2025, reported May 5, 2025: actual 61.27M USD, estimate 78.59M USD, surprise -22.04%, Miss. Q3 2025, reported Aug 4, 2025: actual 78.91M USD, estimate 79.88M USD, surprise -1.22%, Miss. Q4 2025, reported Nov 3, 2025: actual 85.76M USD, estimate 93.8M USD, surprise -8.58%, Miss. Q1 2026, reported Feb 17, 2026: actual 103.59M USD, estimate 93.8M USD, surprise +10.44%, Beat. Q2 2026, reported May 4, 2026: actual 75.27M USD, estimate 70.57M USD, surprise +6.65%, Beat. Q3 2026, reported Aug 10, 2026: actual 85.7M USD, estimate 85.52M USD, surprise +0.21%, Beat. Q4 2026, reported Nov 2, 2026: actual —, estimate 92.66M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

11 ratings
Strong buy00%
Buy873%
Hold19%
Sell218%
Strong sell00%

TCMD news

seekingalpha.com

Tactile Systems Technology, Inc. (TCMD) Q2 2026 Earnings Call Transcript

Tactile Systems Technology, Inc. (TCMD) Q2 2026 Earnings Call Transcript

Read source
marketbeat.com

Tactile Systems Technology Q2 Earnings Call Highlights

Tactile Systems Technology NASDAQ: TCMD, doing business as Tactile Medical, reported second-quarter revenue growth and higher profitability, led by its lymphedema business, while updating its full-year outlook to reflect…

Read source
zacks.com

Tactile Systems Technology (TCMD) Beats Q2 Earnings and Revenue Estimates

Tactile Systems Technology (TCMD) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.14 per share a year ago.

Read source
globenewswire.com

Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026

MINNEAPOLIS, July 21, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today…

Read source
globenewswire.com

Tactile Medical Enters Exclusive U.S. Distribution Agreement with ElastiMed for its MyoSleeve™ Wearable Compression Device for VA and DoD Patients

Discreet, Battery-Powered Device Reaches Patients at Earlier Stages of Disease Progression Discreet, Battery-Powered Device Reaches Patients at Earlier Stages of Disease Progression

Read source
zacks.com

Tactile Systems Technology (TCMD) Moves 8.1% Higher: Will This Strength Last?

Tactile Systems Technology (TCMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Read source

TCMD peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding TCMD

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
19.34M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
13.81M
Weight
0.02%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
7.29M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
4.21M
Weight
0.03%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
3.61M
Weight
0.02%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Dimensional - US Targeted Value ETF logoDimensional - US Targeted Value ETFDFAT
Market value
3.46M
Weight
0.02%
AUM
14.66B USD
Expense ratio
0.28%
Price / 1D
$71.67+0.67%
Fidelity Enhanced Small Cap ETF logoFidelity Enhanced Small Cap ETFFESM
Market value
3.23M
Weight
0.05%
AUM
6.03B USD
Expense ratio
0.28%
Price / 1D
$47.94+0.80%
Avantis U.S. Small Cap Value ETF logoAvantis U.S. Small Cap Value ETFAVUV
Market value
3.13M
Weight
0.01%
AUM
31.27B USD
Expense ratio
0.25%
Price / 1D
$126.45+0.66%

Continue in GoAI

Research TCMD

research.disclaimer